All In Biotech

Drug Trial Radar · NCT03130114

Antibiotics for Children With Severe Diarrhoea

Last checked: Nov 19, 2026Latest source record: May 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 8,268 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,268

Actual

Start

May 13, 2017

Primary completion

Jan 15, 2020

Study completion Jan 15, 2020

Sponsor

Lead sponsor
World Health OrganizationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
International Centre for Diarrhoeal Disease Research, Bangladesh; Center for Public Health Kinetics; Kenya Medical Research Institute; University of Washington; Malawi-Liverpool-Wellcome Trust Clinical Research Programme; University of Liverpool; Centre pour le developpement des vaccines, Mali; University of Maryland, College Park; Aga Khan University; Muhimbili University of Health and Allied Sciences; Boston Children's Hospital
First posted
Apr 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 months, up to 23 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Although the current World Health Organization (WHO) recommended management package for acute diarrhoea (ORS, zinc and feeding advice) has contributed to significant reductions in diarrhoea associated mortality, over half a million children continue to die annually as a result of acute diarrhoeal episodes. In addition, rates of mortality in young children in the 90 days following an episode of acute diarrhoea appear at least as high as mortality that occurs during the acute episode. The long-term benefits of antibiotic administration may result from direct antimicrobial effects on pathogens or from other incompletely understood mechanisms including improved nutrition, alterations in immune tolerance or improved enteric function. Optimizing antibiotic treatment of acute diarrhoea episodes in very young children with severe disease may offer the opportunity to significantly reduce diarrhoea associated deaths in the 180 days following presentation for acute diarrhoea and may also improve growth. The investigators propose to evaluate the efficacy of an antibiotic (azithromycin) delivered in a specific, targeted fashion to young children (\< 2 years of age) at high risk of diarrhoea associated mortality in a multi-site randomized, double-blind, placebo-controlled trial. The study will evaluate the ability of the intervention to reduce mortality within 180 days of the acute diarrhoeal episode, and improve nutritional status over the first 90 days.

Conditions

  • Diarrhea

Interventions

  • AzithromycinDrug

    Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days

  • PlaceboOther

    Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: 180 days from enrolment
  2. Linear growthTime frame: 90 days from enrolment

Locations

7 sites in 7 countries. Site status is shown where the registry gives one.

  • Icddr,B

    Dhaka, Bangladesh

  • Centre for Public Health Kinetics

    New Delhi, India

  • Kenya Medical Research Institute

    Nairobi, Kenya

  • Malawi-Liverpool-Wellcome Trust Clinical Research Programme

    Blantyre, Malawi

  • Centre pour le Développement des Vaccins (CVD-Mali)

    Bamako, Mali

  • Aga Khan University

    Karachi, Pakistan

  • Muhimbili University of Health and Allied Sciences

    Dar es Salaam, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.